Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies

This publication has 9 references indexed in Scilit:

• A systematic review to examine the relationship between objective and patient‐reported outcome measures in sinonasal disorders: recommendations for use in research and clinical practice
  International Forum of Allergy & Rhinology, 2021
• EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management
  Journal of Allergy and Clinical Immunology, 2021
• Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and Possible Therapeutic Implications
  The Journal of Allergy and Clinical Immunology: In Practice, 2020
• Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation
  Allergy, 2019
• Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
  The Lancet, 2019
• The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps
  Rhinology journal, 2019
• Commonality of the IL-4/IL-13 pathway in atopic diseases
  Expert Review of Clinical Immunology, 2017
• Investigation of change in cardinal symptoms of chronic rhinosinusitis after surgical or ongoing medical management
  International Forum of Allergy & Rhinology, 2014
• Prevalence of sinonasal outcome test (SNOT‐22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit
  Clinical Otolaryngology, 2012